Akari Therapeutics

Akari Therapeutics received Patent No. 562,919 from India's Intellectual Property Office for its novel PH1 payload, a spliceosome inhibitor that disrupts RNA splicing to kill cancer cells and activate immune responses.

• Akari Therapeutics has appointed Mark F. Kubik as Head of Business Development - Oncology, bringing over 25 years of experience in transformative deal creation across oncology therapeutics. • Kubik will lead business development activities for Akari's novel antibody-drug conjugate (ADC) platform and its lead asset AKTX-101, which utilizes a first-in-class spliceosome inhibitor payload. • The strategic hire aims to position Akari as a key player in the growing ADC market, capitalizing on increasing Big Pharma interest in early-stage ADC technologies with novel mechanisms of action.

Akari Therapeutics (NASDAQ: AKTX) has successfully priced a $7.6 million private placement financing round, with funds directed toward its spliceosome inhibitor payload ADC technology platform.

NorthSea Therapeutics appoints Melissa Bradford-Klug as CFO/CBO, bringing over 20 years of experience and $6 billion in financing track record to advance metabolic disease therapies.

• Bullous pemphigoid (BP), a subepidermal autoimmune blistering disease primarily affecting the elderly, currently lacks approved therapies in the United States, creating a significant unmet need. • The BP treatment landscape is dominated by off-label corticosteroids and immunosuppressants, highlighting the urgent need for targeted and approved therapies to improve patient outcomes. • Several therapies are in advanced Phase III clinical development, including AstraZeneca's Fasenra, Sanofi/Regeneron's Dupixent, and Akari Therapeutics' nomacopan, signaling potential paradigm shift. • The influx of pipeline therapies aims to address unmet needs, such as diagnostic biomarkers and vulnerable patient population, and could reshape the market dynamics in bullous pemphigoid.